Edition:
India

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

24.80USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$24.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
208,839
52-wk High
$27.80
52-wk Low
$2.70

Chart for

About

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $362.06
Shares Outstanding(Mil.): 24.97
Dividend: --
Yield (%): --

Financials

BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region

* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION

08 Jan 2018

BRIEF-Mirati announces advancement of opportunities with inhibitor programs

* Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs

14 Nov 2017

BRIEF-Mirati Therapeutics reports Q3 loss per share of $0.65

* Mirati Therapeutics reports third quarter 2017 financial results

02 Nov 2017

BRIEF-Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients

* Mirati Therapeutics' mocetinostat included in stand up to cancer's cutting-edge clinical trial initiative for NSCLC patients Source text for Eikon: Further company coverage:

13 Oct 2017

BRIEF-Mirati Therapeutics presents positive data from on-going clinical trials of sitravatinib

* Mirati Therapeutics Inc presents positive preliminary data from on-going clinical trials of sitravatinib in non-small cell lung cancer

15 Sep 2017

BRIEF-Mirati Therapeutics reports Q2 loss per share $0.74

* Mirati Therapeutics reports second quarter 2017 financial results

04 Aug 2017

Earnings vs. Estimates